A Rare Case of Fetal Hydrothorax
Treated through Amniocentesis and Thoracentesis
Dinu-Florin Albu1,
Cristina-Crenguta Albu2, Stefan-Dimitrie Albu3, Mihai Dumitrescu4
1Dr. Dinu-Florin Albu, MD, PhD, Associate Professor, Obstetrics
& Gynecology and Medical Genetics, Expert in Maternal-Fetal
Ultrasound and Maternal-Fetal Medicine, 2Dr. Cristina-Crenguta Albu,
MD, PhD, Associate Professor, Ophthalmology and Medical Genetics, 3Stefan-Dimitrie Albu, Medical Student, 4Mihai Dumitrescu, MD, PhD
Student, Thoracic Surgery and Medical Genetics. All are affiliated with
University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
and Alco San Clinic, Maternal-Fetal Medicine Dept., Bucharest, Romania
Address for
correspondence: Dr. Cristina-Crenguta Albu, E-mail:
stevealbu@yahoo.com, 27A, Catedrei Street, 1st District, 014162,
Bucharest, Romania
Abstract
We present the rare case of a 27-year-old Caucasian female which was
admitted in our service at 27 weeks of gestation after beig discovered
with left fetal hydrothorax during routine prenatal ultrasound. Samples
of maternal blood and amniotic fluid (trough amniocentesis) were
obtained in order to establish the cause (immune or non-immune) and
fetal thoracentesis was performed in order to allow for lung
re-expansion. Analysis of the amniotic and pleural fluids trough QF-PCR
and amniocyte cultures established the diagnosis of Down syndrome and
the decision was taken to perform cesarean section at 33 weeks of
gestation following two weeks treatment with dexamethasone.
Key words:
Fetal Hydrothorax, Amniocentesis, Thoracentesis, Downs Syndrome
Manuscript received:
24th Nov 2014, Reviewed:
6th Dec 2014
Author Corrected;
17th Dec 2014, Accepted
for Publication: 28th Dec 2014
Introduction
Fetal hydrothorax refers to a collection of fluid within the left fetal
thoracic cavity as a result of leakage or generalized fluid retention
from a variety of causes which can be organized into one of the
following diagnostic categories: cardiovascular (21.7%), idiopathic
(17.8%), hematologic (10.4%), syndromic (4.4%), chromosomal (13.4%),
lymphatic dysplasia (5.7%), infections (6.7%), thoracic (6%) and others
(urinary tract alformations, extra-thoracic tumors, placental,
gastrointestinal) [1]. The condition mandates urgent referral to a
maternal fetal medicine specialist for extensive testing because some
situations must be considered prenatal emergencies after 18 weeks and
one should not wait for complete results before initiating minimally
invasive diagnostic procedures and treatment [2].
Case
Report
A 27-year-old Caucasian female, pregnant for the first time, with
negative triple test (AFP, uE3, hCG), was referred at 27 weeks'
gestation for a routine prenatal ultrasound. The couple had normal
general health and was not consanguineous and there was no family
history of genetic disorders. Routine ultrasonography revealed normal
amniotic fluid measurements and a single fetus with a large hydrothorax
(~200ccm) colapsing the left lung and pushing down the driaphragm (Fig.
1). Investigations for determining the cause (non-immune or immune) of
the hydrothorax were carried out and amniocentesis, followed by
thoracentesis, were performed. From the maternal blood acute phase
titers were checked for syphilis, rubella parvovirus, tohoplasmosis,
cytomegalovirus, rubella and antibody screening thorough indirect
Coombs was performed. The amniotic fluid (sample of 40ml) was tested for possible infection
with parvovirus B19, toxoplasma, cytomegalovirus by use of PCR, while
amniocyte cultures and QF-PCR were conducted in order to detect a
possible genetic disorders.
Fig 1: 2D ultrasound
showing 27 weeks fetus with
hydrothorax
Fig. 2:
Karyotype obtained from amniocyte culture showing Trisomy 21
For thoracentesis we used the same sampling kit used for amniocentesis
and a sample of 70ccm pleural fluid was obtained at 28 weeks of
gestation by using ultrasound guidance. Post procedural ultrasound
examination revealed positive lung expansion. Karyotype and QF-PCR from
both amniotic fluid and thoracic fluid indicated the presence of
Trisomy 21 (Fig. 2) and the decision was taken to perform a cesarean
section at 33 weeks of gestation following a two weeks treatment with
dexamethasone. Postoperative period was uneventfull and the newborn
developed normally, weekly ultrasound examinations showing decreasingly
amounts of pleural fluid with complete resorbtion observed at 8 weeks
after birth.
Discussion
Despite extensive investigations, the etiology of fetal hydrothorax
remains unknown in 15% to 25% of patients [3,4] while chromosomal
abnormalities are the cause of fetal hydrothorax in 25% to 70% of cases
[5]. Standard fetal chromosome analysis is indicated in all cases of
fetal hydrothorax and early referral to a maternal–fetal
specialist allows for detailed and comprehensive ultrasound examination
and the early identification of any treatable causes [6]. A careful
search for structural fetal anomalies or genetic syndromes, signs of
fetal infection, and evidence of umbilical cord or placental anomalies
may rapidly indicate the cause of fetal hydrothorax while fetal
karyotyping and genetic microarray molecular testing should be
conducted in all cases of unexplained hydrothorax. Cytogenetic
laboratories can provide a fast but limited results within 24 to 48
hours by using QF-PCR (amniotic fluid) or more detailed results by
karyotyping (amniotic fluid, fetal blood). Also, amniotic fluid should
also be obtained for viral and bacterial cultures, viral PCR tests, and
karyotyping [7]. Although cases of spontaneous resolution have been
cited for fetal hydrothorax [8,9], we took the decision to perform
amniocentesis with thoracentesis since the perinatal mortality of
untreated fetal hydrothorax is still high [10] and some others have
reported complete resolution after single thoracentesis [11,12,13].
Conclusions
Even though the use of prenatal techniques (amniocentesis) for the
treatment of fetal hydrothorax is still debatable with different
authors reporting higher survival rates for either the conservative
management [9] or the prenatal interventions [13,14, 15], we do
advocate that each case of fetal hydrothorax should be investigated for
genetic disorders by use of minimally invasive techniques such as
chorionic villus sampling or amniocentesis and that improved access to
specialized maternal–fetal medicine centers for fetal
evaluation and treatment can improve outcome.
Funding:
Nil, Conflict of
interest:
Nil
Permission from IRB:
Yes
References
1. Braun T, Brauer M, Fuchs I, Czernik C, Dudenhausen JW, Henrich W, et
al, Mirror syndrome: a systematic review of fetal associated
conditions, maternal presentation and perinatal outcome, Fetal Diagn
Ther. 2010;27(4):191-203. doi: 10.1159/000305096.
2. Désilets V, Audibert F; Society of Obstetrician and
Gynaecologists of Canada, Investigation and management of non-immune
fetal hydrops, J Obstet Gynaecol Can, 2013, 35(10):923-38. [PubMed]
3. Bellini C, Hennekam RC, Bonioli E, A diagnostic flow chart for
non-immune hydrops fetalis, Am J Med Genet A. 2009 May;149A(5):852-3. [PubMed]
4. Santo S, Mansour S, Thilaganathan B, Homfray T, Papageorghiou A,
Calvert S, et al, Prenatal diagnosis of non-immune hydrops fetalis:
what do we tell the parents, Prenat Diagn, 2011, 31:186–195. [PubMed]
5. Jauniaux E, Van Maldergem L, De Munter C, Moscoso G, Gillerot Y,
Nonimmune hydrops fetalis associated with genetic abnormalities, Obstet
Gynecol, 1990, 75:568–572. [PubMed]
6. Hansen T, Non immune hydrops fetalis, In: Rudolph A, Kamei R, Overby
K (eds). Rudolph’s pediatrics. 21st ed., McGraw-Hill, New
York, 2003.
7. Ramsay SL, Maire I, Bindloss C, Fuller M, Whitfield PD, Piraud M, et
al, Determination of oligosaccharides and glycolipids in amniotic fluid
by electrospray ionisation tandem mass spectrometry: in utero
indicators of lysosomal storage diseases, Mol Gene Metab 2004,
83:231–238.
8. Weber AM, Philipson EH, Ingardia CJ, Spontaneous resolution of
second trimester fetal pleural effusion,J Matern Fetal Neonatal Med,
1992, 1(2):87-89.
9. Klam S, Bigras JL, Hudon L, Predicting outcome in primary fetal
hydrothorax, Fetal Diagn Ther, 2005, 20(5):366-370. [PubMed]
10. Yinon Y, Kely E, Ryan G, Fetal pleural effusions, Best Pract Res
Clin Obstet Gynaecol, 2008, 22(1):77-96. [PubMed]
11. Hidaka N, Chiba Y, fetal hydrothorax resolving completely aftera
single thoracentesis: a report of 2 cases, J Reprod Med, 2007,
52(9):843-848.
12. Alkazaleh F, Saleem M, Badran E, Intrathoracic displacement of
pleuroamniotic shunt after successful in utero treatment of fetal
hydrops secondary to hydrothorax. Case report and review of the
literature, Fetal Diagn Ther, 2009, 25(1):40-43. [PubMed]
13. Derderian SC, Trivedi S, Farrell J, Keller RL, Rand L, et al,
Outcomes of fetal intervention for primary hydrothorax, J Pediatr Surg,
2014, 49(6):900-903. [PubMed]
14. Petersen S, Kaur R, Thomas JT, Cincotta R, Gardener G. The outcome
of isolated primary fetal hydrothorax: a 10-year review from a tertiary
center, Fetal Diagn Ther., 2013, 34(2):69-76. [PubMed]
15. Albu D. , Dumitrescu M. , Albu C. , Severin E. Fetal hydrotorax,
Presented at the 61th Annual Meeting of The American Society of Human
Genetics, Oct. 11 - 15, 2011, Montreal, Canada.
How to cite this article?
Dinu-Florin Albu, Cristina-Crenguta Albu, Stefan-Dimitrie Albu, Mihai
Dumitrescu. A Rare Case of Fetal Hydrothorax treated through
Amniocentesis and Thoracentesis. Int J Med Res Rev 2015;3(1):118-120.doi:10.17511/ijmrr.2015.i01.020.